| |
 |
 |
|
| |
Address:
377 Saw Creek Estates,
Bushkill, PA18324, USA
Tel: +1 570-588-3854
Fax: +1 702-995-3905
+1 570-588-3213
Email:
info@pharmachinaonline.com |
| |
|
|
 |
| |
| |
|
 |
| |
| Title: |
MicuRx Pharma names new preclinical candidate 2008) |
| Type： |
Pharmaceutical Chemical(NCE) |
| Status： |
Preclinical |
Targeted
Indication(s): |
-drug resistant gram-positive bacteria |
| Developer(s): |
MicuRx Pharmaceuticals, Inc. |
Description
/Summary： |
MicuRx Pharmaceuticals, Inc., a US biopharmaceutical company with R&D based in China, announced on August 18 the nomination of MRX-I as its first preclinical development candidate. MRX-I is an antibacterial molecule targeting multi-drug resistant gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).
|
Additional
Info/Comments: |
"MRX-I and additional MicuRx pipeline leads have been identified using our proprietary drug discovery platform," commented Mike F. Gordeev, Ph.D., executive vice president and chief scientific officer of MicuRx. "We will continue to leverage this novel platform to further enhance the pharmacological properties and safety profile of clinically validated antibiotic classes, creating best-in-class antibiotics capable of addressing the growing problem of the bacterial multi-drug resistance." |
|
|
